Louise von Stechow

Pharma and Biotech - Consultant / Communication Expert

Dr. Louise von Stechow is a biotech expert and strategy consultant for the pharmaceutical and biotech industries. Through her podcast, as a keynote speaker, science writer, and lecturer, she explores the role of revolutionary biotechnologies such as artificial intelligence in drug development and their impact on business and society. Louise has a PhD in biology, with a focus on systems biology.
Louise writes a monthly column on how new technologies can help tackle the challenges of diagnosing, treating, and managing rare diseases.

Contributing Author in
AI & Digital

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Louise

AI-Based Next-Generation-Phenotyping for Rare Disease Diagnosis

Rare diseases, which affect more than 300 million people worldwide, are often difficult to diagnose. Many patients wait five years or more for a correct diagnosis and are misdiagnosed at least once along this diagnostic odyssey. In addition to being a significant burden to patients’ well-being, low diagnostic rates also impact research and development in the rare disease space and challenge the success of marketed orphan drugs.

From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US Orphan Drug Act and 1999 EU Orphan Regulation, provide regulatory and economic incentives to drug developers. Despite an increase in the number of annually FDA-approved drugs with an orphan designation from 2 in 1983 to 33 in 2020, more than 90% of rare diseases still lack effective therapies.